下一代减毒黄热病疫苗候选株vYF-247的小动物模型安全性与免疫效力
研究从Stamaril®和YF-VAX®谱系制备24株YF-17D候选亚株,筛选出神经毒力最低且免疫原性不劣于现有疫苗的vYF-247。vYF-247源自YF-VAX谱系,相对亲本有5个核苷酸差异,仅2个导致氨基酸改变。小鼠中vYF-247神经毒力低于Stamaril和YF-VAX,在A129小鼠中神经侵袭和内脏侵袭特征与YF-VAX相似,在仓鼠中免疫原性良好并保护免受致死性攻击。
要点
- vYF-247源自YF-VAX谱系,相对亲本有5个核苷酸差异,仅2个导致氨基酸改变。
- 小鼠中vYF-247神经毒力低于Stamaril和YF-VAX,不受生产阶段影响。
- A129小鼠中vYF-247神经侵袭和内脏侵袭特征与YF-VAX相似,预期不增加YEL-AVD或YEL-AND风险。
核心结论
- vYF-247在动物模型中神经毒力低于现有疫苗,免疫原性和保护效力与现有黄热病疫苗相当。
研究设计与样本
- 临床前研究:从Stamaril®和YF-VAX®谱系通过转染病毒基因组RNA至无血清培养的Vero细胞制备24株YF-17D候选亚株。
- 筛选出神经毒力、神经侵袭和内脏侵袭最低且免疫原性至少与Stamaril和YF-VAX可比的克隆作为候选疫苗vYF-247。
- 在小鼠、A129小鼠(缺乏I型IFN受体)和仓鼠中评估安全性与免疫效力。
主要发现
- vYF-247源自YF-VAX谱系,相对亲本有5个核苷酸差异,仅2个导致氨基酸改变:包膜蛋白E第480位缬氨酸变为亮氨酸,非结构蛋白NS2A第65位甲硫氨酸变为缬氨酸。
- 小鼠中vYF-247神经毒力低于Stamaril和YF-VAX,不受生产阶段影响。
- A129小鼠中vYF-247神经侵袭和内脏侵袭特征与YF-VAX相似。
- 仓鼠中vYF-247免疫原性良好,保护免受致死性Jimenez P10 YF病毒攻击引起的高病毒血症和死亡。
关键数值与推荐
- 筛选标准:神经毒力、神经侵袭和内脏侵袭最低,免疫原性至少与Stamaril和YF-VAX可比。
- vYF-247相对亲本有5个核苷酸差异,仅2个导致氨基酸改变。
临床怎么用
- vYF-247预期在人类中提供与现有黄热病疫苗相似的强效保护,且不增加YEL-AVD或YEL-AND风险。
局限性
- 研究仅在小动物模型中进行,尚未在人类中验证安全性和免疫效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Yellow fever (YF) remains a threat to human health in tropical regions of Africa and South America. Live-attenuated YF-17D vaccines have proven to be safe and effective in protecting travellers and populations in endemic regions against YF, despite very rare severe reactions following vaccination - YF vaccine-associated viscerotropic disease (YEL-AVD) and neurological disease (YEL-AND). We describe the generation and selection of a live-attenuated YF-17D vaccine candidate and present its preclinical profile. Initially, 24 YF-17D vaccine candidate sub-strains from the Stamaril® and YF-VAX® lineage were created through transfection of viral genomic RNA into Vero cells cultured in serum-free media to produce seed lots. The clone with the 'optimal' preclinical profile, i.e. the lowest neurovirulence, neurotropism and viscerotropism, and immunogenicity at least comparable with Stamaril and YF-VAX in relevant animal models, was selected as the vaccine candidate and taken forward for assessment at various production stages. The 'optimal' vaccine candidate was obtained from the YF-VAX lineage (hence named vYF-247) and had five nucleotide differences relative to its parent, with only two changes that resulted in amino acid changes at position 480 of the envelope protein (E) (valine to leucine), and position 65 of the non-structural protein 2A (NS2A) (methionine to valine). vYF-247 was less neurovirulent in mice than Stamaril and YF-VAX irrespective of production stage. Its attenuation profile in terms of neurotropism and viscerotropism was similar to YF-VAX in A129 mice, a 'worst case' animal model lacking type-I IFN receptors required to initiate viral clearance. Thus, vYF-247 would not be expected to have higher rates of YEL-AVD or YEL-AND than Stamaril and YF-VAX. In hamsters, vYF-247 was immunogenic and protected against high viremia and death induced by a lethal challenge with the hamster-adapted Jimenez P10 YF virus strain. Our data suggests that vYF-247 would provide robust protection against YF disease in humans, similar to currently marketed YF vaccines.
引用
- Piras-Douce F, Raynal F, Raquin A, et al. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models. Vaccine. 2021. PMID: 33685778. doi:10.1016/j.vaccine.2021.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。